Tratuzumab, which has been used in clinical therapy for 20 years, is one of the most effective anti-HER2 antibodies in breast and gastric cancer, yet it shows a limited curative effect due to tumor acquired resistance. This evidence concerns the gene ERBB2 and neoplasm.